


Aragen Cell Line Development Solutions for Biologics CHO CLD Platforms



Aragen offers choice of CLD platforms



RapTr 2022TM: Increased Titer & Reduced Timeline of CLD Process Flow

CHO CLD Platforms

- CHO DG44, CHO GS, CHOZN, SP 2/0
- Our in-house developed CHO DG44 platform can deliver titer >4g/L in 5 months CHO GS: up to 6g/L- royalty free, milestone payment free, difficult-to-express proteins, NBEs, and animal health
- Over 100 CLD programs Pre-IND/GMP
- Over 14 in clinical development and 3+ commercial production.

Key Attributes

- RapTr2022 with Aragen offers choice of CLD platforms
- Royalty-free CHO DG44 best suited for biosimilar development.
- Royalty free, accelerated timeline for DG44 and CHO GS (18 weeks from transfection to RCB)
- Transfection to single cell clone evaluation in 18 weeks with Aragen's optimized process
- Our CLD platform uses a chemically defined serum free medium and proof of clonality to support IND filing
- Strong Analytical capabilities early engagement to establish quality and select right clones to advance

Aragen's Process Development Solutions for Biologics CHO CLD Platforms

Aragen offers coefficient upstream and downstream process development

- We use nonproprietary commercially available media and feed for screening studies this allows transfer to any CDMO
- Media and feed screening in shake flasks
- Process parameter screening and optimization in AMBR250
- Process consistency and scalability happens in 1L, 5L & 10L bioreactor



Downstream Process Development



Key Attributes

- Ambr250 platform for upstream process development-synergies to reduce time to IND
- Fully automated AMBR250 24 units, integrated to NOVA Flex-2 & Vi-Cell
- Multifactorial DOE to screen process parameters like-pH, DO, Temp, agitation etc
- Process parameter optimization and identifying best operative parameters
- History of generating biosimilar cell lines- now in market

Let's begin the Conversation





